Press Release

WiseGuyReports has added new market study to its database, titled “2019 Global and Regional Cystitis Market Research Report Forecast 2025”.

Report Overview:

Cystitis is usually not severe and may be awkward if left untreated, but may lead to complications. Bacterial infection most often causes cystitis. Cystitis is described as inflammation of the bladder, which is typically caused by bladder infection, according to the National Health Service. In the majority of cases, mild cystitis resolves within a couple of days. Usually Cystitis is caused if the urethra and bladder are infected with bacteria which are generally sterile or microbe-free. Bacteria attach to the bladder lining, resulting in irritating and inflaming the region.

Cystitis impacts both men and women of all ages. It is more prevalent in women than in men as women have smaller urethra. Roughly 80% of all UTIs are induced by bacteria from the bowel reaching the urinary tract. It is estimated that one in five females will have at least one UTI during their lifetime, according to the National Kidney Foundation. Almost 20% of females with a UTI will have another, and 30% will have one more. In view of the increasing incidence of cystitis, progress is required globally for patients.

Request Free Sample Report at:

Market Dynamics: Drivers, Restraints, Opportunities Challenges
• Increasing prevalence of UTI to drive the market for Cystitis
The infection of the urinary line is more frequent in females because of their anatomy than in males. More than once in their lives, several females experience urinary tract infection. Some studies suggest that the disease of the urinary tract impacts about 150 million individuals worldwide. Furthermore, about 11% of females visit a doctor in one year to receive therapy with urinary tract infections. Some of the primary triggers for urinary tract infection include hormonal modifications, inappropriate personal hygiene, catheter use, and other variables. The urinary tract infection market is projected to grow significantly in the next few years as the incidence of urinary tract infection increases.
• Use of urinary catheters and other drainage devices is likely to provide a boost to market growth in Cystitis.
The increasing incidence of chronic kidney disease, such as cancer of the bladder and renal failure, has resulted to increased use in patients of catheters and other drainage devices. Patients who use urinary catheters are more likely to get complex UTI. The danger of bacterium for patients using urinary catheters is about 5% per day, according to the World Health Organization (WHO), and 40% suffer from nosocomial infections. Some variables, such as extended catheterization length, failure to receive antibiotic system treatment, bacterial colonization in drainage bags, fast underlying fata illnesses, and others, are probable to lead to catheter-associated infection. Increasing the use of urinary catheters will therefore promote development in the market for therapy for cystitis infection.

View Detailed, Report at :

Key Segments
Cystitis Market by Drug Class

• Penicillin and Combinations
• Quinolones
• Cephalosporin
• Aminoglycoside Antibiotics
• Sulphonamides (Sulfamethoxazole +Trimethoprim)
• Azoles and Amphotericin B
• Tetracycline (Doxycycline)
• Nirtofurans (Nitrofurantoin)
• Others

Cystitis Market by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• E-commerce/ online Pharmacies

Competitive Landscape:
The worldwide therapeutic market for urinary tract infection is extremely competitive and is made up of several significant players. Novartis AG, Pfizer, Merlion Pharma, GlaxoSmithKline PLC, Cipla, Inc., Bayer AG, AstraZeneca, Almirall SA and Merck & Co.,Inc.

We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

About us:

Wise Guy Reports are a part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the global.

Contact Us:

[email protected]
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)